New antiepileptic drugs: Focus on ezogabine, clobazam, and perampanel

Leslie A. Rudzinski, Nayme J. Vlez-Ruiz, Evan R. Gedzelman, Elizabeth A. Mauricio, Jerry J. Shih, Ioannis Karakis

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Ezogabine, clobazam, and perampanel are among the newest antiseizure drugs approved by the Food and Drug Administration between 2011 and 2012. Ezogabine and perampanel are approved for adjunctive treatment of partial epilepsy. Perampanel is also approved for adjunctive treatment of primary generalized tonicclonic seizures. Ezogabine and perampanel have novel mechanisms of action. Ezogabine binds to voltage-gated potassium channels and increases the M-current thereby causing membrane hyperpolarization. Perampanel is a selective, non-competitive 2-amino-3-(3- hydroxy-5-methyl-isoxazol-4-yl)propanoic acid receptor antagonist, which reduces neuronal excitation. Clobazam has been used worldwide since the 1970s and is approved for adjunctive treatment of seizures associated with Lennox- Gastaut syndrome. Clobazam is the only 1,5- benzodiazepine currently in clinical use, which is less sedating than the commonly used 1,4- benzodiazepines. Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated efficacy and good tolerability of these 3 new antiepileptic drugs. These drugs represent a welcome addition to the armamentarium of practitioners, but it remains to be seen how they will affect the landscape of pharmacoresistant epilepsy.

Original languageEnglish (US)
Pages (from-to)1087-1101
Number of pages15
JournalJournal of Investigative Medicine
Volume64
Issue number6
DOIs
StatePublished - Aug 1 2016

Fingerprint

Anticonvulsants
Seizures
Voltage-Gated Potassium Channels
Partial Epilepsy
United States Food and Drug Administration
Benzodiazepines
Pharmaceutical Preparations
Epilepsy
Therapeutics
Placebos
perampanel
ezogabine
clobazam
Membranes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Rudzinski, L. A., Vlez-Ruiz, N. J., Gedzelman, E. R., Mauricio, E. A., Shih, J. J., & Karakis, I. (2016). New antiepileptic drugs: Focus on ezogabine, clobazam, and perampanel. Journal of Investigative Medicine, 64(6), 1087-1101. https://doi.org/10.1136/jim-2016-000151

New antiepileptic drugs : Focus on ezogabine, clobazam, and perampanel. / Rudzinski, Leslie A.; Vlez-Ruiz, Nayme J.; Gedzelman, Evan R.; Mauricio, Elizabeth A.; Shih, Jerry J.; Karakis, Ioannis.

In: Journal of Investigative Medicine, Vol. 64, No. 6, 01.08.2016, p. 1087-1101.

Research output: Contribution to journalReview article

Rudzinski, LA, Vlez-Ruiz, NJ, Gedzelman, ER, Mauricio, EA, Shih, JJ & Karakis, I 2016, 'New antiepileptic drugs: Focus on ezogabine, clobazam, and perampanel', Journal of Investigative Medicine, vol. 64, no. 6, pp. 1087-1101. https://doi.org/10.1136/jim-2016-000151
Rudzinski LA, Vlez-Ruiz NJ, Gedzelman ER, Mauricio EA, Shih JJ, Karakis I. New antiepileptic drugs: Focus on ezogabine, clobazam, and perampanel. Journal of Investigative Medicine. 2016 Aug 1;64(6):1087-1101. https://doi.org/10.1136/jim-2016-000151
Rudzinski, Leslie A. ; Vlez-Ruiz, Nayme J. ; Gedzelman, Evan R. ; Mauricio, Elizabeth A. ; Shih, Jerry J. ; Karakis, Ioannis. / New antiepileptic drugs : Focus on ezogabine, clobazam, and perampanel. In: Journal of Investigative Medicine. 2016 ; Vol. 64, No. 6. pp. 1087-1101.
@article{9085cb13fa15411e80fec14ec9901bd9,
title = "New antiepileptic drugs: Focus on ezogabine, clobazam, and perampanel",
abstract = "Ezogabine, clobazam, and perampanel are among the newest antiseizure drugs approved by the Food and Drug Administration between 2011 and 2012. Ezogabine and perampanel are approved for adjunctive treatment of partial epilepsy. Perampanel is also approved for adjunctive treatment of primary generalized tonicclonic seizures. Ezogabine and perampanel have novel mechanisms of action. Ezogabine binds to voltage-gated potassium channels and increases the M-current thereby causing membrane hyperpolarization. Perampanel is a selective, non-competitive 2-amino-3-(3- hydroxy-5-methyl-isoxazol-4-yl)propanoic acid receptor antagonist, which reduces neuronal excitation. Clobazam has been used worldwide since the 1970s and is approved for adjunctive treatment of seizures associated with Lennox- Gastaut syndrome. Clobazam is the only 1,5- benzodiazepine currently in clinical use, which is less sedating than the commonly used 1,4- benzodiazepines. Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated efficacy and good tolerability of these 3 new antiepileptic drugs. These drugs represent a welcome addition to the armamentarium of practitioners, but it remains to be seen how they will affect the landscape of pharmacoresistant epilepsy.",
author = "Rudzinski, {Leslie A.} and Vlez-Ruiz, {Nayme J.} and Gedzelman, {Evan R.} and Mauricio, {Elizabeth A.} and Shih, {Jerry J.} and Ioannis Karakis",
year = "2016",
month = "8",
day = "1",
doi = "10.1136/jim-2016-000151",
language = "English (US)",
volume = "64",
pages = "1087--1101",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - New antiepileptic drugs

T2 - Focus on ezogabine, clobazam, and perampanel

AU - Rudzinski, Leslie A.

AU - Vlez-Ruiz, Nayme J.

AU - Gedzelman, Evan R.

AU - Mauricio, Elizabeth A.

AU - Shih, Jerry J.

AU - Karakis, Ioannis

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Ezogabine, clobazam, and perampanel are among the newest antiseizure drugs approved by the Food and Drug Administration between 2011 and 2012. Ezogabine and perampanel are approved for adjunctive treatment of partial epilepsy. Perampanel is also approved for adjunctive treatment of primary generalized tonicclonic seizures. Ezogabine and perampanel have novel mechanisms of action. Ezogabine binds to voltage-gated potassium channels and increases the M-current thereby causing membrane hyperpolarization. Perampanel is a selective, non-competitive 2-amino-3-(3- hydroxy-5-methyl-isoxazol-4-yl)propanoic acid receptor antagonist, which reduces neuronal excitation. Clobazam has been used worldwide since the 1970s and is approved for adjunctive treatment of seizures associated with Lennox- Gastaut syndrome. Clobazam is the only 1,5- benzodiazepine currently in clinical use, which is less sedating than the commonly used 1,4- benzodiazepines. Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated efficacy and good tolerability of these 3 new antiepileptic drugs. These drugs represent a welcome addition to the armamentarium of practitioners, but it remains to be seen how they will affect the landscape of pharmacoresistant epilepsy.

AB - Ezogabine, clobazam, and perampanel are among the newest antiseizure drugs approved by the Food and Drug Administration between 2011 and 2012. Ezogabine and perampanel are approved for adjunctive treatment of partial epilepsy. Perampanel is also approved for adjunctive treatment of primary generalized tonicclonic seizures. Ezogabine and perampanel have novel mechanisms of action. Ezogabine binds to voltage-gated potassium channels and increases the M-current thereby causing membrane hyperpolarization. Perampanel is a selective, non-competitive 2-amino-3-(3- hydroxy-5-methyl-isoxazol-4-yl)propanoic acid receptor antagonist, which reduces neuronal excitation. Clobazam has been used worldwide since the 1970s and is approved for adjunctive treatment of seizures associated with Lennox- Gastaut syndrome. Clobazam is the only 1,5- benzodiazepine currently in clinical use, which is less sedating than the commonly used 1,4- benzodiazepines. Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated efficacy and good tolerability of these 3 new antiepileptic drugs. These drugs represent a welcome addition to the armamentarium of practitioners, but it remains to be seen how they will affect the landscape of pharmacoresistant epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=85006097024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006097024&partnerID=8YFLogxK

U2 - 10.1136/jim-2016-000151

DO - 10.1136/jim-2016-000151

M3 - Review article

C2 - 27252470

AN - SCOPUS:85006097024

VL - 64

SP - 1087

EP - 1101

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 6

ER -